NZ554924A - Combination of 2-[4-[2-(benzimidazole-2-ylthio)ethyl]piperazin-1-yl]-N-[2,4-bis(methylthio)-6-methyl-3-pyridyl]acetamide and pitavastatin - Google Patents

Combination of 2-[4-[2-(benzimidazole-2-ylthio)ethyl]piperazin-1-yl]-N-[2,4-bis(methylthio)-6-methyl-3-pyridyl]acetamide and pitavastatin

Info

Publication number
NZ554924A
NZ554924A NZ554924A NZ55492405A NZ554924A NZ 554924 A NZ554924 A NZ 554924A NZ 554924 A NZ554924 A NZ 554924A NZ 55492405 A NZ55492405 A NZ 55492405A NZ 554924 A NZ554924 A NZ 554924A
Authority
NZ
New Zealand
Prior art keywords
compound
pitavastatin
pharmaceutically acceptable
effective amount
hydrate
Prior art date
Application number
NZ554924A
Other languages
English (en)
Inventor
Hideyuki Kobayashi
Yasunobu Yoshinaka
Kimiyuki Shibuya
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of NZ554924A publication Critical patent/NZ554924A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ554924A 2004-12-10 2005-12-09 Combination of 2-[4-[2-(benzimidazole-2-ylthio)ethyl]piperazin-1-yl]-N-[2,4-bis(methylthio)-6-methyl-3-pyridyl]acetamide and pitavastatin NZ554924A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63453204P 2004-12-10 2004-12-10
PCT/JP2005/023088 WO2006064889A1 (en) 2004-12-10 2005-12-09 Method for reduction, stabilization and prevention of rupture of lipid rich plaque

Publications (1)

Publication Number Publication Date
NZ554924A true NZ554924A (en) 2010-09-30

Family

ID=36587943

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ554924A NZ554924A (en) 2004-12-10 2005-12-09 Combination of 2-[4-[2-(benzimidazole-2-ylthio)ethyl]piperazin-1-yl]-N-[2,4-bis(methylthio)-6-methyl-3-pyridyl]acetamide and pitavastatin

Country Status (11)

Country Link
US (2) US20090275595A1 (enExample)
EP (1) EP1827440A4 (enExample)
JP (1) JP2008522955A (enExample)
KR (1) KR100895031B1 (enExample)
CN (1) CN101068548B (enExample)
AU (1) AU2005314810B2 (enExample)
CA (1) CA2590224C (enExample)
NZ (1) NZ554924A (enExample)
RU (1) RU2351337C1 (enExample)
TW (1) TW200619204A (enExample)
WO (1) WO2006064889A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060111898A (ko) * 2003-08-29 2006-10-30 교와 가부시키가이샤 지질-풍부-플라크의 안정화 방법 및 파열 예방방법
US8048083B2 (en) * 2004-11-05 2011-11-01 Dfine, Inc. Bone treatment systems and methods
WO2011081118A1 (ja) * 2009-12-29 2011-07-07 興和株式会社 経口投与用医薬組成物
CN102711762A (zh) * 2009-12-29 2012-10-03 兴和株式会社 口服用固体医药组合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) * 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
US5177080A (en) * 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
CZ127198A3 (cs) * 1995-11-02 1998-12-16 Warner-Lambert Company Způsob regulace koncentrace lipidů a farmaceutická kompozice pro tento způsob
US6969711B2 (en) * 1997-05-26 2005-11-29 Kowa Company, Ltd. Cyclic diamine compounds and medicine containing the same
HUP0002294A3 (en) * 1997-05-26 2001-10-29 Kowa Co Cyclic diamine compounds and medicines containing the same
RU2235483C2 (ru) * 1998-11-25 2004-09-10 Нутри Фарма Аса Композиция, фармацевтический препарат и способ для профилактики и/или лечения и/или ослабления сердечно-сосудистых заболеваний
WO2001022962A1 (en) * 1999-09-30 2001-04-05 Merck & Co., Inc. Anti-hypercholesterolemic drug combination
US6974806B2 (en) * 2000-07-13 2005-12-13 Takeda Pharmaceutical Company Limited Lipid-rich plaque inhibitors
AU8254101A (en) * 2000-09-01 2002-03-22 Sankyo Co Medicinal compositions
US20060165605A1 (en) * 2001-12-28 2006-07-27 Ye-Mon Chen Process to regenerate fcc spent catalyst
MY140618A (en) * 2003-02-28 2009-12-31 Kowa Co Method for preparing acid addition salts of polyacidic basic compounds
US20060046996A1 (en) * 2004-08-31 2006-03-02 Kowa Co., Ltd. Method for treating hyperlipidemia

Also Published As

Publication number Publication date
AU2005314810B2 (en) 2010-08-26
TW200619204A (en) 2006-06-16
EP1827440A1 (en) 2007-09-05
CA2590224A1 (en) 2006-06-22
CN101068548B (zh) 2010-12-08
CN101068548A (zh) 2007-11-07
RU2007125976A (ru) 2009-01-20
JP2008522955A (ja) 2008-07-03
US20110207742A1 (en) 2011-08-25
HK1111356A1 (en) 2008-08-08
US20090275595A1 (en) 2009-11-05
EP1827440A4 (en) 2010-12-08
KR20070085508A (ko) 2007-08-27
KR100895031B1 (ko) 2009-04-24
WO2006064889A1 (en) 2006-06-22
AU2005314810A1 (en) 2006-06-22
CA2590224C (en) 2011-12-20
RU2351337C1 (ru) 2009-04-10

Similar Documents

Publication Publication Date Title
US5674893A (en) Method for preventing reducing or risk of onset of cerebrovascular events employing an HMG CoA reductase inhibitor
US20040023840A1 (en) Combination of organic compounds
CZ286832B6 (en) Compound pharmaceutical preparation for prevention and treatment of arteriosclerosis or xanthoma
US20110015206A1 (en) Method of stabilizing lipid-rich plaque and method of preventing rupture thereof
KR20050012771A (ko) 치환된 시아노피롤리딘의 용도 및 이들을 함유하는고지혈증 및 관련 질환의 치료를 위한 조합 제제
EP2787993B1 (en) TREATMENT OF ARTERIAL WALL BY COMBINATION OF RAAS INHIBITOR AND HMG-CoA REDUCTASE INHIBITOR
US20110207742A1 (en) Method for reduction, stabilization and prevention of rupture of lipid rich plaque
US20150272944A1 (en) Novel triglyceride reducing agent
CN1330309C (zh) 用于预防或治疗由eNOS表达而引起的疾病的药物
CA2548790A1 (en) Medicinal compositions and combinations
WO2002030425A1 (en) Preventives and remedies for complications of diabetes
Kurata et al. Cerivastatin induces carotid artery plaque stabilization independently of cholesterol lowering in patients with hypercholesterolaemia
MXPA06006831A (es) Uso de estatinas para el tratamiento del sindrome metabolico.
HK1111356B (en) Method for reduction, stabilization and prevention of rupture of lipid rich plaque
US7750033B2 (en) Preventive and remedy for collagen or elastin metabolic disorder
WO2004091660A1 (ja) Lklf/klf2遺伝子発現促進剤
WO2006011495A1 (ja) 高コレステロール血症及び／又は高トリグリセリド血症治療剤
US20100041716A1 (en) Nitroxides for use in treating or preventing hypercholesterolemia
CA3268864A1 (en) ONCE DAILY ALDOSTERONE SYNTHASE INHIBITOR (R)-(+)-5-(P-CYANOPHENYL)-5,6,7,8-TETRAHYDROIMIDAZO[L,5-AjPYRIDINE
JP2006176498A (ja) 血中遊離脂肪酸低下作用を有する医薬組成物

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
LAPS Patent lapsed